[Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].

Q4 Medicine
Jing Jia, Nian Liu, Yin Wu
{"title":"[Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].","authors":"Jing Jia, Nian Liu, Yin Wu","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical characteristics and outcomes of multiple myeloma (MM) patients infected with <i>Listeria monocytogenes</i> (LM) in novel agent era, so as to improve clinicians' understanding.</p><p><strong>Methods: </strong>Clinical data of 4 MM patients infected with LM in Beijing Chao-yang Hospital from October 2018 to October 2022 was analyzed retrospectively.</p><p><strong>Results: </strong>The average age of the 4 patients was (57.5±4.1) years old. All the patients did not reach deep remission from induction therapy or experienced multiple recurrences of MM, with significant decreased immunoglobulin levels and lymphocyte counts. The initial clinical manifestation was all fever. Three patients developed nervous system symptoms 2-3 days after onset and cerebrospinal fluid examination indicated meningitis. The sensitive anti-infection agents were given according to pathogenic test results 4-5 days after onset. After treatment, two patients recovered, one patient gave up treatment and died after discharged from hospital, and one critical patient died despite exposure to sensitive antibiotics.</p><p><strong>Conclusion: </strong>MM patients, with the application of novel agents, may have increased risk of LM infection, even critical cases. LM prevention and prompt therapy in early stage for suspected patients is key to reducing the risk of severe infection and mortality.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"157-162"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To analyze the clinical characteristics and outcomes of multiple myeloma (MM) patients infected with Listeria monocytogenes (LM) in novel agent era, so as to improve clinicians' understanding.

Methods: Clinical data of 4 MM patients infected with LM in Beijing Chao-yang Hospital from October 2018 to October 2022 was analyzed retrospectively.

Results: The average age of the 4 patients was (57.5±4.1) years old. All the patients did not reach deep remission from induction therapy or experienced multiple recurrences of MM, with significant decreased immunoglobulin levels and lymphocyte counts. The initial clinical manifestation was all fever. Three patients developed nervous system symptoms 2-3 days after onset and cerebrospinal fluid examination indicated meningitis. The sensitive anti-infection agents were given according to pathogenic test results 4-5 days after onset. After treatment, two patients recovered, one patient gave up treatment and died after discharged from hospital, and one critical patient died despite exposure to sensitive antibiotics.

Conclusion: MM patients, with the application of novel agents, may have increased risk of LM infection, even critical cases. LM prevention and prompt therapy in early stage for suspected patients is key to reducing the risk of severe infection and mortality.

新型药物治疗多发性骨髓瘤李斯特菌病临床分析
目的:分析新型药物时代多发性骨髓瘤(MM)患者感染单核增生李斯特菌(Listeria monocytogenes, LM)的临床特点及预后,以提高临床医生的认识。方法:回顾性分析北京朝阳医院2018年10月至2022年10月收治的4例MM感染LM患者的临床资料。结果:4例患者平均年龄为(57.5±4.1)岁。所有患者诱导治疗后均未达到深度缓解或MM多次复发,免疫球蛋白水平和淋巴细胞计数明显下降。最初临床表现均为发热。3例患者发病2-3天后出现神经系统症状,脑脊液检查提示脑膜炎。发病后4 ~ 5天根据病原学试验结果给予敏感抗感染药物。经治疗,2例患者康复,1例患者放弃治疗,出院后死亡,1例危重患者因接触敏感抗生素死亡。结论:MM患者应用新型药物后,可能会增加LM感染的风险,甚至出现危重病例。对疑似患者进行早期预防和及时治疗是降低严重感染和死亡风险的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中国实验血液学杂志
中国实验血液学杂志 Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
7331
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信